Assignee
SYNDAX PHARMACEUTICALS INC
US·7 granted patents·17 pending applications·6 citations·filing 2008–2024
Top patents by PatentIndex Score
24 records- 0185US11919901B2Inhibitors of the menin-MLL interactionSYNDAX PHARMACEUTICALS INC·Filed 2022·Granted Mar 5, 2024·1 cites·28 claims
- 0281US11397184B2Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2016·Granted Jul 26, 2022·2 cites·19 claims
- 0380US11324822B2Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Granted May 10, 2022·3 cites·24 claims
- 0476US2024398944A1Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0575US2025064925A1Method of treating cancer using a combination of entinostat and an anti-csf-1r antibodySYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0674US2024288425A1Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0770US2023022573A1Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0868US2023061048A1Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0966US2010305167A1Administration of an Inhibitor of HDACSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1064US2025011441A1Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibodySYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1163US12000829B2Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2019·Granted Jun 4, 2024·0 cites·18 claims
- 1259US12168054B2Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibodySYNDAX PHARMACEUTICALS INC·Filed 2018·Granted Dec 17, 2024·0 cites·22 claims
- 1358US2009149511A1Administration of an Inhibitor of HDAC and an mTOR InhibitorSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1458US2025295661A1Menin-mll inhibitors for the treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1557US12564590B2Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereofSYNDAX PHARMACEUTICALS INC·Filed 2021·Granted Mar 3, 2026·0 cites·32 claims
- 1655US2024238291A1Combinations for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1751US2010267779A1Novel Compounds and Methods of Using ThemSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1851US2025170132A1Salts and polymorphic forms of menin inhibitors and pharmaceutical compositions thereofSYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1951US2010298270A1Novel Compounds and Methods of Using ThemSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2049US12552869B2CSF-1R antibodies for the treatment of chronic graft versus host diseaseSYNDAX PHARMACEUTICALS INC·Filed 2020·Granted Feb 17, 2026·0 cites·31 claims
- 2149US2019343844A1Methods for the treatment of breast cancerSYNDAX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2246US2013150386A1Methods for the treatment of lung cancerSYNDAX PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2337US2018353602A1Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2435US2019290759A1Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →